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Elevated blood pressure is the most common chronic
illness in the United States, affecting more than 50
million people. Hypertension is an even greater prob-
lem in the African American community. Tradition-
ally, management of hypertension and cardiovascular
risk reduction has focused on drug therapy; however,
several studies have shown the benefits of therapeutic
lifestyle changes for blood pressure lowering and car-
diovascular risk reduction. Therapeutic lifestyle
changes to reduce blood pressure have enormous
potential as a means for preventing and controlling
hypertension and thereby reducing the risk of coro-
nary heart disease. Although the reductions in blood
pressure are relatively modest with these approaches,
they could potentially have a beneficial impact on
overall cardiovascular morbidity and mortality when
applied to the whole population. Because of their high
prevalence of certain cardiovascular risk factors (e.g.,
obesity, diabetes mellitus) and greater salt sensitivity,
therapeutic lifestyle changes have particular relevance
for African Americans. (J Clin Hypertens. 2003;
5(1 suppl 1):32–37) ©2003 Le Jacq Communications, Inc.
Elevated blood pressure is the most commonchronic illness in the United States, affecting
more than 50 million people, and hypertension is an
even greater health problem in the African American
community.1 Approximately 33% of adult African
Americans and 25% of adult white persons in the
United States have hypertension.2,3 Furthermore,
African Americans have higher rates of morbidity
and mortality, earlier onset of hypertension, and
more hypertension-related cardiovascular complica-
tions than other American ethnic groups.2,4
Traditionally, management of hypertension and
cardiovascular risk reduction have focused on
drug therapy.5 Although the use of antihyperten-
sive drugs and other pharmacologic agents for
cardiovascular risk reduction dominates the man-
agement of these conditions and has shown enor-
mous benefit, several studies have also demon-
strated the benefits of therapeutic lifestyle changes
for blood pressure lowering and cardiovascular
risk reduction.6–10
Multifaceted therapeutic lifestyle changes are 
an integral component in decreasing hypertension
and reducing the risk for coronary heart disease
(CHD).11,12 Recommendations from the Sixth
Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of
High Blood Pressure11 and more recently from the
National High Blood Pressure Education Program12
emphasize a number of therapeutic lifestyle changes
for the management of hypertension. These include
weight reduction for those who are overweight,
moderation of alcohol intake, increased physical
activity, moderation of dietary sodium, adequate in-
take of dietary potassium, adequate intake of dietary
calcium and magnesium, cessation of smoking, and
reduced intake of dietary saturated fat and cholesterol.
These changes are considered essential for individuals
who are more likely to develop high blood pressure,
such as African Americans, the elderly, and those who
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are overweight and physically inactive or have a strong
family history of hypertension.
Patients should be strongly encouraged to adopt
these lifestyle modifications, particularly if they have
additional risk factors for cardiovascular disease.
Even when these therapeutic lifestyle changes do not
reduce blood pressure to normal levels, their use can
decrease the dosages of antihypertensive medications
that are required.11 Because African Americans have
a higher prevalence of certain cardiovascular risk fac-
tors (e.g., obesity, cigarette smoking, type 2 diabetes),
they may be more responsive to lifestyle modifica-
tions than other racial groups.11 In addition, these
individuals are generally more sensitive to changes in
certain dietary factors (particularly sodium intake)
than the general population.11
Therapeutic lifestyle changes are important for
individuals with hypertension and are particularly
important for those with elevated cardiovascular
disease risk factors such as hyperlipidemia and dia-
betes. This report reviews data showing the benefit
of therapeutic lifestyle changes in the management
of hypertension and cardiovascular risk reduction.
THERAPEUTIC LIFESTYLE CHANGES 
Because patients with hypertension are at increased
risk for CHD, therapeutic lifestyle changes that
decrease cardiovascular risk are of the utmost impor-
tance. Patient education regarding therapeutic lifestyle
changes to lower blood pressure, serum cholesterol
levels, and the risk for CHD is crucial. Although many
of the studies assessing the efficacy of therapeutic
lifestyle changes do not specify the proportion of
patients who are African American, the results are
likely applicable across ethnic groups.
Diet
DASH and DASH-Sodium. Two recent trials (Dietary
Approaches to Stop Hypertension [DASH]13 and
DASH-Sodium14) have shown that dietary manage-
ment can reduce blood pressure. Overall, these studies
show that a diet low in saturated fat, cholesterol, and
total fat that emphasizes fruits, vegetables, and low-fat
dairy foods will reduce blood pressure.
The DASH trial13 studied 459 individuals with
systolic blood pressure (SBP) <160 mm Hg and dias-
tolic blood pressure (DBP) 80–95 mm Hg; 60%
were African Americans. Subjects were randomized
to one of three diets: 1) control diet; 2) a diet rich in
fruits and vegetables; or 3) a combination diet rich
in fruits, vegetables, and low-fat dairy products with
reduced saturated and total fat (Table).14 SBP and
DBP were decreased by 5.5 and 3.0 mm Hg, respec-
tively, in those randomized to the combination diet
compared to the control diet (p<0.001). The effect
was even greater among African Americans (6.9/3.7
mm Hg reductions; p<0.001). Among those with
hypertension at baseline, the reductions in SBP and
DBP were 11.4 and 5.5 mm Hg, and these blood
pressure reductions were evident within 2 weeks.
Subjects randomized to the fruits-and-vegetables
diet also had a decrease in blood pressure but to a
lesser extent than subjects on the combination diet.
The combination diet decreased SBP and DBP by
2.7/1.9 mm Hg more than the fruits-and-vegetables
diet (p≤0.001). The benefit of the combination diet
over the other diets was evident in both patients
with and without hypertension.
The DASH-Sodium study15 was a randomized, mul-
ticenter trial designed to evaluate the effect of different
levels of dietary sodium, in conjunction with the DASH
diet, on blood pressure. This study included 412
patients (56%–57% African American) with an aver-
age SBP and DBP of 120–159/80–95 mm Hg. Subjects
were randomized to a DASH or control diet for 1
month at each of three sodium levels (1500, 2400, or
3300 mg/day). The reductions in blood pressure were
greatest among those on the DASH diet with the low-
est sodium level, a level below that routinely recom-
mended in national guidelines. SBP was reduced by
11.5 mm Hg more in patients randomized to the
DASH diet and a lower level of sodium than the con-
trol diet and a high level of sodium (p<0.001). The
effect was even greater among African American
patients (difference of 12.6 mm Hg; p<0.001).
Restriction of dietary sodium gradually reduced blood
pressure for both eating plans. The difference in SBP
between the low- and high-sodium subgroups was 6.7
mm Hg for the control diet (p<0.001) and 3.0 mm Hg
for the DASH diet (p<0.001). Reductions in blood
pressure were seen without respect to the presence of
hypertension, race, or sex.16 
Mediterranean-Type Diet and Omega-3 Fatty Acids.
The Lyon Diet Heart Study10 was a prospective, ran-
domized, secondary prevention diet modification trial
designed to see if a Mediterranean diet rich in α-
linolenic acid (an omega-3 fatty acid found in large
amounts in flaxseed oil) is more effective than a typi-
cal low-fat diet in preventing recurrent cardiac events
among patients who had experienced a first myocar-
dial infarction. The experimental group replaced most
of their meat with chicken and replaced butter with
margarine high in α-linolenic acid. After 4 years, the
experimental group had fewer cardiac events than the
control group on three separate composite outcomes.
This included fewer primary (cardiac death and non-
fatal myocardial infarction) events (14 vs. 44 events;
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p=0.0001); fewer primary and secondary (unstable
angina, stroke, heart failure, pulmonary or peripheral
embolism) events (27 vs. 90 events, p=0.0001); and
fewer primary, secondary, and minor events requiring
hospitalization (95 vs. 180 events, p=0.0002). 
The largest study of omega-3 fats was the GISSI
Prevenzione Trial (Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico),17 in which
more than 11,000 Italian subjects were randomized to
an omega-3 fatty acid supplement (n-3 polyunsaturat-
ed fatty acid), vitamin E, or control following myocar-
dial infarction. After 3.5 years, the omega-3 fatty acid
group had a 10% (95% confidence interval [CI], 1–18)
relative risk reduction for the composite end point
(death, nonfatal myocardial infarction, and stroke).
The benefit was primarily related to a decrease in the
risk of death (14% risk reduction [95% CI, 3–24]). 
The exact mechanisms of benefit of omega-3 fatty
acids are not fully known but may relate to their mod-
est blood pressure-lowering effects, their triglyceride-
lowering effects, or their antiplatelet effects. From epi-
demiologic data and clinical trial evidence, it seems
that just two servings of omega-3 fatty acid–contain-
ing fish per week are associated with a 40% decrease
in CHD death. Ocean fish such as salmon, tuna, and
mackerel have the highest levels of omega-3 fatty
acids, although fresh water species such as lake trout
and channel catfish also contain significant amounts.
Weight Reduction and Increased Physical Activity
Excess body weight and a sedentary lifestyle are cor-
related with the development of hypertension. There
has been a progressive trend toward decreased phys-
ical activity among Americans in general and African
Americans in particular during the past several years,
and this has contributed to the increased prevalence
of obesity. For example, Kimm et al.18 recently re-
ported that 56% of 16- and 17-year-old African
American girls participate in no leisure-time physical
activity compared with 31% of white girls. In this
study, a decline in physical activity was significantly
associated with a higher body mass index (BMI) for
both groups (p≤0.05 for both). Excess weight (par-
ticularly abdominal obesity) and physical inactivity
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Table. The Dietary Approaches to Stop Hypertension (DASH) Eating Plan*
FOOD GROUP
DAILY





7–8 1 slice bread, 1/2 cup dry
cereal, 1/2 cup cooked
rice, pasta, or cereal
Whole-wheat bread, English




Vegetables 4–5 1 cup raw leafy
vegetable, 1/2 cup
cooked vegetable, 6 oz
vegetable juice
Tomatoes, potatoes, carrots,
peas, squash, broccoli, turnip
greens, collards, kale, spinach,




Fruits 4–5 6 oz fruit juice, 1
medium fruit, 1/4 cup
dried fruit, 1/2 cup fresh,














2–3 8 oz milk, 1 cup yogurt,
1.5 oz cheese
Skim or 1% milk, skim or low-
fat buttermilk, nonfat or low-







2 or less 3 oz cooked meats,
poultry, or fish
Select only lean; trim away
visible fats; broil, roast, or boil









1.5 oz or 1/3 cup nuts,
1/2 oz or 2 tbsp seeds,
1/2 cup cooked legumes
Almonds, filberts, mixed nuts,
peanuts, walnuts, sunflower





*Based on 2000 calories/day
Reproduced from the National Heart, Lung, and Blood Institute Publication, Facts About DASH Diet.14
are risk factors for insulin resistance and enhance the
risk for CHD. 
Although therapeutic lifestyle changes such as
weight loss and physical activity are frequently recom-
mended for the treatment of hypertension in the elder-
ly, there has been a paucity of evidence from random-
ized controlled trials in support of this recommenda-
tion. A 1998 trial,19,20 however, offered proof of ben-
efit of this approach. The Trial of Nonpharmacologic
Interventions in the Elderly (TONE)19,20 was designed
to determine whether weight loss or reduced sodium
intake are effective in the treatment of older persons
with hypertension. This was a randomized controlled
trial of 875 men and women aged 60–80 years with
SBP <145 mm Hg and DBP <85 mm Hg. All partici-
pants received treatment with a single antihypertensive
medication. Of the 975 participants (proportion of
African Americans not specified), 585 were obese. The
585 obese participants were randomized to reduced
sodium intake, weight loss, both, or usual care, and
the 390 nonobese participants were randomized to
reduced sodium intake or usual care. Withdrawal of
antihypertensive medication was attempted after 3
months of intervention. The main outcomes measured
were high blood pressure at one or more follow-up vis-
its, treatment with antihypertensive medication, or a
cardiovascular event during follow-up (range, 15–36
months; median, 29 months). 
The results of this trial showed that the combined
outcome measure was less frequent among those
assigned to reduced sodium intake (relative hazard
ratio, 0.69; 95% CI, 0.59–0.81; p<0.001) and, in
obese participants, among those assigned to weight
loss (relative hazard ratio, 0.70; 95% CI, 0.57–0.87;
p<0.001). Relative to usual care, hazard ratios
among the obese participants were 0.60 (95% CI,
0.45–0.80; p<0.001) for reduced sodium intake
alone, 0.64 (95% CI, 0.49–0.85; p=0.002) for
weight loss alone, and 0.47 (95% CI, 0.35–0.64;
p<0.001) for reduced sodium intake and weight loss
combined. The frequency of cardiovascular events
during follow-up was similar in each of the six treat-
ment groups. Additional follow-up after the end of
TONE found that the benefits of standard dietary
intervention had persisted for at least 4 years.20
Forty-eight months after the end of contact with the
study investigators, more patients randomized to the
combined interaction group were not taking antihy-
pertensive medication compared with the usual-care
group (23% vs. 7%; p=0.012). It can be concluded
from this study that reduced sodium intake and
weight loss constitute feasible, effective, and safe
therapeutic lifestyle changes for the treatment of
hypertension in older persons. 
Similar results were shown in the Trials of
Hypertension Prevention (TOHP) phase II,20,21 which
involved 2382 middle-aged men and women with
high-normal blood pressure (83–89/≤140 mm Hg)
and a BMI 110%–165% above normal standards.21,22
Participants were randomized to receive counseling for
weight loss and/or sodium restriction (each alone and
in combination) or to a control group. 
Participants in the weight-reduction group achieved
mean reductions in weight of 4.4, 2.0, and 0.2 kg at 6,
18, and 36 months.22 Although white participants
achieved significantly greater reductions in weight than
African Americans in the first 18 months of the study,
the difference was not evident at 36 months. DBP and
SBP decreased more in all of the active treatment
groups than in the control group throughout the 36-
month follow-up period. Compared with the control
group, blood pressure was reduced 3.7/2.7 mm Hg in
the weight-loss group, 2.9/1.6 mm Hg in the sodium-
reduction group, and 4.0/2.8 mm Hg in the combined
group (p<0.001 for all groups vs. control).20 There
were no racial differences in responses at all time
points. There was a positive correlation between the
degree of weight loss and the degree of blood pressure
reduction.22 Of note, there seemed to be a residual
effect on blood pressure among those who lost weight
initially but subsequently regained their lost weight,
with these participants having a significantly lower rel-
ative risk (0.68; 95% CI, 0.47–1.00) for hypertension
compared with patients with no weight loss. 
These studies show that even modest reductions in
weight are associated with significant reductions in
SBP and DBP. It has been estimated that each 1-kg
reduction in body weight is associated with reductions
in SBP and DBP, respectively, of 1.2 and 1.0 mm Hg.23
Such reductions in blood pressure can have a substan-
tial clinical benefit. The recent guidelines of the
National High Blood Pressure Education Program
estimate that a reduction in SBP as little as 2 mm Hg
could save more than 70,000 lives in the United States
each year.12
According to the American Heart Association, the
goal is to achieve a BMI of ≤18.5 kg/m2. The
American Heart Association recommends that weight
management be initiated when BMI is ≥25 kg/m2 and
waist circumference at the iliac crest level is >40 inch-
es in men and >35 inches in women.24 A weight-man-
agement program should include caloric restriction
and increased caloric expenditure as appropriate.
Moderately-intense physical activity (40%–60% of
maximum oxygen consumption) can lower blood
pressure.11 Increased physical activity can also reduce
the risk for CHD, improve glucose control, and
improve overall well-being.25
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THERAPY FOR HYPERCHOLESTEROLEMIA 
The National Cholesterol Education Program recently
revised its guidelines for the detection, evaluation, and
treatment of elevated cholesterol levels (Adult
Treatment Panel III [ATP III]).26 The ATP III guidelines
continue to recognize low-density lipoprotein (LDL)
cholesterol as the major cause of CHD. This recogni-
tion and the results of large studies showing the benefit
of aggressive LDL-lowering therapy has resulted in a
lowering of target LDL cholesterol levels. An LDL cho-
lesterol level <100 mg/dL is now classified as optimal.26
Based on an increased recognition of the importance of
high-density lipoprotein (HDL) cholesterol, categoric
low HDL cholesterol was increased from <35 mg/dL to
<40 mg/dL in ATP III. The finding that elevated triglyc-
eride levels are an independent CHD risk factor led to
the lowering of triglyceride classification cutpoints to
give more attention to moderate elevations. In addi-
tion, the ATP III guidelines place special emphasis on
the identification of individuals with multiple metabol-
ic risk factors (i.e., metabolic syndrome) as candidates
for intensive therapeutic lifestyle changes. 
Pharmacologic therapy for elevated blood choles-
terol levels, primarily with statins, has been shown to
decrease mortality and CHD both in the primary and
secondary prevention settings (Figure).27 Diet is also
an important factor for lowering serum cholesterol
levels. The ATP III recommendations for the treatment
of high blood cholesterol recommend a reduced intake
of saturated fats (<7% of total calories) and choles-
terol (<200 mg/day).26 Total fat is allowed to range
from 25%–35% of total calories provided that satu-
rated fats and trans-fatty acids are kept low. This is
because a higher intake of unsaturated fat can help 
to reduce triglyceride and increase HDL cholesterol 
levels, particularly among those with the metabolic
syndrome. The DASH28 diet has also been shown to
produce significant reductions in total, LDL, and HDL
cholesterol levels. Patients randomized to the DASH
diet achieved reductions in total and LDL cholesterol
levels of 13.7 mg/dL and 10.7 mg/dL, respectively,
more than those in the control diet group (p<0.0001).
The effect was similar across racial groups. Although
specific studies have not been done in black subjects,
the guidelines for lipid control most certainly would
apply to this population.
CONCLUSIONS 
Great strides have been made in reducing morbidity
and mortality from heart disease in this century.
However, CHD is still the single largest killer of
Americans. We have seen enormous benefits with the
advent of pharmacologic agents for the treatment of
cardiovascular risk factors, and even greater benefits
can be seen if both pharmacologic and therapeutic
lifestyle measures are used in conjunction. Therapeutic
lifestyle approaches to reducing blood pressure have
enormous potential as a means for preventing and
controlling hypertension and thereby reducing the risk
of CHD. Indeed, even if the reduction in blood pres-
sure with therapeutic lifestyle changes is small, an
enormous, beneficial impact on overall cardiovascular
morbidity and mortality can be achieved when the
benefits are applied to the whole US population.
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